Delivery Order SPE2DB24D2205-SPE2DB25FEHJG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $9,326.81 delivery order to AmerisourceBergen Drug Corp for 30-count bottles of Xcopri 200 mg tablets, with an ultimate completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 150 mg, with an ultimate completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xcopri 100 mg tablets (30-count units) with a ceiling value of $2,947.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract has an ultimate completion date of July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,178.96 for Xcopri 100 mg tablets (30-count units) on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,080.32 on September 2, 2025, for the supply of Xcopri 200 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract was issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded a delivery order valued at $1.9K to AmerisourceBergen Drug Corp for Xcopri 200 mg tablets (30-count units) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by August 13, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery from its corporate office location in the same municipality. This delivery...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHJGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,794.23 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 150 mg tablets, with a completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and provides a global pharmaceutical support vehicle for military healthcare programs. The contract enables the company to supply a broad range of pharmaceutical products, medical supplies, brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains. Xcopri (cenobamate) is a neurological treatment used for seizure management, demonstrating AmerisourceBergen's role in fulfilling specialized pharmaceutical requirements for federal healthcare systems including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/10/25 |